Xeris Biopharma Holdings (XERS) Treasury Shares (2020 - 2026)

Xeris Biopharma Holdings has reported Treasury Shares for 7 years, with the latest figure at $9.7 million in Q1 2026.

• For the quarter ending Q1 2026, Treasury Shares fell 36.04% year-over-year to $9.7 million; the trailing twelve-month figure through Mar 2026 stood at $9.7 million (down 36.04% YoY), and the FY2025 full-year result was $13.5 million, down 17.72% from the prior year.
• Treasury Shares for Q1 2026 stood at $9.7 million, down from $13.5 million in the prior quarter.
• The five-year high for Treasury Shares was $16.4 million in Q4 2024, with the low at $5.3 million in Q4 2022.
• Historically, Treasury Shares has averaged $12.5 million across 5 years, with a median of $13.6 million in 2025.
• Annual changes were most pronounced in 2023 — Treasury Shares surged 120.33% — and 2026, when it sank 36.04%.
• Xeris Biopharma Holdings' Treasury Shares stood at $5.3 million in 2022, then surged by 120.33% to $11.6 million in 2023, then jumped by 41.81% to $16.4 million in 2024, then retreated by 17.72% to $13.5 million in 2025, then decreased by 28.38% to $9.7 million in 2026.
• The last three Treasury Shares figures came in at $9.7 million (Q1 2026), $13.5 million (Q4 2025), and $13.8 million (Q3 2025), per Business Quant data.